Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Unresectable Esophageal Cancer Clinical Trial

Official title:
A Phase II Trial of Combination of Toripalimab and Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Status Completed

Clinical Trial Summary

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody) combined with definitive CRT in locally advanced esophageal squamous cell carcinoma (ESCC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Esophageal Neoplasms
Esophageal Squamous Cell Carcinoma
Unresectable Esophageal Cancer

Clinical Trial Details

NCT number	NCT04005170
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Completed
Phase	Phase 2
Start date	June 25, 2019
Completion date	July 31, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04137679` - Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO	Phase 2
	Recruiting	`NCT06251973` - A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	Phase 2